Skip to content
Search

Latest Stories

O’Briens Pharmacy Group disposes of Blackpool site after strategic review

O’Briens Pharmacy Group disposes of Blackpool site after strategic review

The popular Blackpool pharmacy business has been acquired by a first-time buyer

O’Briens Pharmacy Group has sold Bispham Pharmacy as part of a strategic review of its nine-site portfolio, now reduced to eight, across the Fylde coast region.

Christie and Co, the property adviser, recently announced that the group’s popular Blackpool pharmacy business has been acquired by first-time buyer, Arif Bhuriya.


Bispham Pharmacy, which dispenses around 4,500 items per month, is situated in the heart of Bispham’s commercial centre, opposite a bustling shopping area. The community pharmacy has been in this location since February 2021, following a minor contract relocation.

O'Briens Pharmacy Group provides pharmacy services across Fleetwood, Thornton-Cleveleys, Bispham, Burscough, Liverpool, and surrounding areas.

Aisling O’Brien, owner of O’Briens Pharmacy, explained the rationale behind selling the Bispham site: “When we had a strategic review of our group, we saw Bispham as an ideal site to dispose of, knowing it would fare much better in the current climate as an owner-operated site.

“Naturally, we called Christie and Co and, whilst there was a good deal of interest in the site, it was pleasing to do the deal with Arif whom I am familiar with as a fellow LPC member. We wish him all the very best with the business in the future.”

Bhuriya, the new owner, plans to build on the pharmacy’s steady growth, particularly following the closure of a nearby Lloyds Pharmacy in Sainsbury’s last year. He aims to further increase item numbers while maintaining a focus on high levels of customer service and service delivery.

Having finally acquired his first pharmacy business after searching for a couple of years, Arif expressed his excitement:

“Bispham was an area which I am familiar with so when I saw the opportunity hit the market, I knew that it was a site that I could take to the next level. The hard work starts now but I’d like to thank Aisling O’Brien for all her help in working towards a successful sale and I am excited to start work on my plans for the business and the people of Bispham.”

Jon Booth, Director of Pharmacy at Christie and Co, who managed  the confidential sales process, highlighted the nature of the deal: “Whilst this deal was not without the usual challenges around funding and property matters, it is very much the type of deal we have seen in volume across the Northwest this year.”

Booth believes that as an owner-operator, Arif can identify improvements and make changes by being directly involved in the daily operations of the pharmacy, delivering first-class service to local patients.

Craig Dickson, Director at Christie Finance, who assisted Arif in securing the funding, is confident that Arif will be hands-on in running the pharmacy, and the business will thrive under his ownership.

“Arif had been looking to acquire his first pharmacy for some time and, after a few false starts, he identified Bispham as an ideal opportunity moving forward.

“I met with him, explained the funding process, then put together a pack of supporting information for our lender contacts and quickly secured excellent terms. Arif will be very much hands-on being the owner pharmacist and I’m sure the business will go from strength to strength,” Dickson said.

The sale price of Bispham Pharmacy was not disclosed.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less